Need Help?

TRACERx 100: RNAseq data from the first 100 TRACERx tumours

TRACERx (TRAcking Cancer Evolution through therapy (Rx)) is a prospective cohort study designed to investigate intratumor heterogeneity (ITH) in relation to clinical outcome, and to determine the clonal nature of driver events and evolutionary processes in early stage non-small cell lung cancer (NSCLC). This study looks at the multi-region RNAseq data from the TRACERx100 cohort with high enough quality RNA available. There is RNAseq data from 164 regions (64 patients).

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001004591 Illumina HiSeq 4000 164
Publications Citations
Neoantigen-directed immune escape in lung cancer evolution.
Nature 567: 2019 479-485
470
Understanding the impact of immune-mediated selection on lung cancer evolution.
Br J Cancer 124: 2021 1615-1617
3
Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.
Nat Biotechnol 40: 2022 1624-1633
28
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
Nat Cancer 4: 2023 608-628
22
Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin.
J Clin Invest 133: 2023 e164397
6
Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion.
iScience 27: 2024 110529
0
Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer.
NPJ Precis Oncol 8: 2024 225
0